Clinical Study Program Articles & Analysis: Older
5 news found
The clinical trial has been authorized by Health Canada, who also recently approved an amendment to the research protocol to increase the dosage of the study drug up to 100 mg of CBD to be assessed in the study. ...
"Importantly, these Phase 2 findings enabled us to advance REL-1017 into the multiple clinical studies RELIANCE Phase 3 program for REL-1017 in MDD." About REL-1017 REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic ...
By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ideas to a clinical start in two years. ...
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) ...
Biopticon Corporation Announces the release of the new version of their innovative TumorManagerTM Program for managing pre-clinical oncology study data Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today released the latest version of ...